Finance
Company focused on transdermal science reports Q2 2005 results, business update
Published in Hepatitis Weekly, September 5th, 2005
For the 3 months ended June 30, 2005, the net loss applicable to common stockholders was $1,753,000, or $.08 per share, as compared to $1,407,000, or $.09 per share, for the same period in 2004. For the 6 months ended June 30, 2005, the net loss applicable to common stockholders was $3,045,000, or $.14 per share, as compared to $2,810,000, or $.19 per share, for the same period in 2004.
The company ended the quarter with $6,833,000 in cash and short-term investments and expects that these funds will be sufficient to fund...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-09-05)
More Articles from Hepatitis Weekly
- Complementary & Alternative Medicine
Garlic oil and DDB have a hepatoprotective effect while lowering plasma lipids - Hepatitis B Vaccine
HBV vaccine questionable in patients receiving lamividine post liver transplant - Hepatitis B Virus
Company announces end of patient dosing in HepeX-B hepatitis B phase II trial - Hepatitis C Virus
Donor age above 50 increases risk of recurrence after liver transplantation - Hepatitis C Virus
Further study of the adiponectin/insulin resistance/HCV infection triad needed - Autoimmune Disease
MICA-mimicking peptides show promise in explaining NKG2D-related autoimmunity - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
